Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Majalah Obstetri dan Ginekologi Neurologico Spinale Medico Chirurgico
de Liyis, Bryan Gervais
2nd Year Medical Student, Udayana University
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Role of Rho-kinase Inhibitor and hrsACE2 in COVID-19 Patients Management Wilson Halim; Bryan Gervais de Liyis; Cokorda Istri Intan Dalem Sukawati
Neurologico Spinale Medico Chirurgico Vol 5 No 1 (2022)
Publisher : Indoscholar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36444/nsmc.v5i1.201

Abstract

The Renin-angiotensin system (RAS) plays an important role in the SARS-CoV-2 infection through Angiotensin-converting enzyme 2 (ACE2). Human recombinant soluble ACE2 (hrsACE2) has been shown to act as a competitive interceptor for SARS-CoV-2 by preventing the binding of viral particles to the ACE2. In addition, Rho-kinase inhibitors have been proven to suppress SARS-CoV-2 infection through inhibition of the Rho-associated protein kinase (ROCK) pathway. The combined effect of hrsACE2 and Rho-kinase inhibitor increases the activity and levels of ACE2 in protection through the Ang1-7 MasR, Ang1-9, and other mechanisms of protection. This literature review is done by searching journals with “COVID-19”, “ACE2”, “hrsACE2”, “Rho- kinase inhibitor”, and “ROCK pathway” as well as Boolean logic “AND” and “OR”. Relevant journals are used as references to compile systematic writing. Based on research results, hrsACE2 and Rho-kinase inhibitors have been clinically proven to protect tissue through the elevated level of ACE2 by the mechanism of Rho-kinase inhibitor, which increased Ang1-7 MasR concentration that gives vasodilatation, anti-proliferative, anti-inflammation, and anti-fibrotic effect. Rho-kinase inhibitors significantly reduce the number of infected cells by SARS-CoV-2 in COVID-19 patients. The potential of the combination therapy of Rho-kinase inhibitor and hrsACE2 therapy can be an efficient therapeutic solution for COVID-19 patients so that further research can be carried out in the future.
Body fat percentage and Body Mass Index in association with menstrual irregularities in young adults: A cross-sectional study de Liyis, Bryan Gervais; David, George; Gunawan, Made Favian Budi
Majalah Obstetri & Ginekologi Vol. 32 No. 2 (2024): August
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/mog.V32I22024.80-88

Abstract

HIGHLIGHTS 1. Body fat percentage and BMI were found to be associated with menstrual cycle and menstrual bleeding period.2. The odds of having a prolonged menstrual cycle were increased by a factor of 1.109 with an increase of one unit of body fat percentage, while the odds of having a prolonged menstrual bleeding period was decreased by a factor 0.887 with an increase of one unit of body fat percentage.   ABSTRACT Objectives: Body fat percentage measures overall amount of fat as a proportion of total body weight. Basal metabolic index (BMI) is an unreliable predictor of body fat percentage as excess fat, lean, muscle, or bone density are indifferentiable. However, the relation between body fat percentage and BMI on menstrual characteristics are still unclear. The aim was to compare the correlations between body fat percentage and BMI towards menstrual characteristics.Materials and Methods: A cross-sectional sample of 211 young adults was taken by means of cluster random sampling. Cross tabulations were performed between variables and Pearson's chi square value were observed. Multiple logistic regressions were performed to observe the odds ratio and 95% confidence interval.Results: Body fat percentage was found to be associated with menstrual cycle (p=0.000) and menstrual bleeding period (p=0.000) but not daily pads usage, intermenstrual bleeding, and menstrual pains. Age was found not to correlate with any of the collected menstrual characteristic data. BMI was also found to be associated with menstrual cycle (p=0.008) and menstrual bleeding period (p=0.003). Further analysis showed that a one unit increase of body fat percentage was linearly correlated with increased of menstrual cycle by a factor of 1.109 days (p<0.01) and a decreased of menstrual bleeding period by a factor of 0.887 days (p<0.01).Conclusion: Although both body fat percentage and BMI showed associations with menstrual cycle and menstrual bleeding period, only body fat percentage was linearly correlated with menstrual cycle and menstrual bleeding period.
Maternal-related factors associated with development and improvement of peripartum cardiomyopathy and therapeutic outcomes of bromocriptine Pradnyaandara, I Gusti Bagus Mulia Agung; Mulyana, Ryan Saktika; Sutedja, Jane Carissa; Jagannatha, Gusti Ngurah Prana; Wibawa, I Bagus Satriya; Deantri, Fanny; Pradnyana, I Wayan Agus Surya; de Liyis, Bryan Gervais
Majalah Obstetri & Ginekologi Vol. 32 No. 2 (2024): August
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/mog.V32I22024.112-127

Abstract

HIGHLIGHTS Younger age, black race, normotension, and multiparity indicate a poorer prognosis for peripartum cardiomyopathy recovery, while bromocriptine therapy reduces adverse events.   ABSTRACT Objectives: This study aimed to fill the significant knowledge gap regarding peripartum cardiomyopathy (PPCM), a heart failure phenotype linked to pregnancy. The main objectives were to explore the factors influencing the development and progression of PPCM and to assess the outcomes of bromocriptine.Materials and Methods: Systematic search across PubMed, ScienceDirect, and Cochrane Library identified studies until December 2022. This study includes non-randomized prospective and retrospective studies, as well as relevant randomized controlled trials. Risk factors were compared between the recovered and non-recovered PPCM groups, and bromocriptine therapy outcomes were evaluated against standard heart failure treatment as the primary endpoint.Results: The analysis included 24 observational studies and 1 randomized controlled trial involving 1,651 PPCM patients; 9 studies evaluating the outcomes of bromocriptine therapy. The most prevalent factors were caesarean delivery (proportion=53%, 95%CI=41%-66%) and anemia (proportion=51%, 95%CI=38%-65%). Non-recovered patients were younger (MD=-1.04 years old, 95%CI=-1.82-(-0.27), p=0.008) and predominantly black (RR=1.82, 95%CI=1.43-2.31, p <0.001). Hypertensive disorders and primiparity were found less among non-recovered patients (RR=0.73, 95%CI=0.60-0.88, p=0.001; RR=0.81, 95%CI=0.66-0.99, p=0.04, respectively). Non-recovered patients also exhibited higher baseline serum creatinine levels, lower LVEF, larger left ventricular end-systolic diameter (LVESD), larger left ventricular end-diastolic diameter (LVEDD), and lower fractional shortening (all P-values<0.05). Furthermore, bromocriptine significantly reduced major adverse cardiac events (MACE), mortality, and increased LVEF (all P-values<0.05).Conclusion: Younger maternal age, black race, absence of hypertension, and multiparity are associated with poorer prognosis for PPCM recovery. Bromocriptine therapy demonstrates superior benefits in reducing adverse events in PPCM.
Co-Authors Cokorda Istri Intan Dalem Sukawati David, George Deantri, Fanny Gunawan, Made Favian Budi Jagannatha, Gusti Ngurah Prana Pradnyaandara, I Gusti Bagus Mulia Agung Pradnyana, I Wayan Agus Surya Ryan Saktika Mulyana Sutedja, Jane Carissa Wibawa, I Bagus Satriya Wilson Halim